Donald R Durden

US Patent:

20200181164, Jun 11, 2020

Filed:

Jun 5, 2018

Appl. No.:

16/619625

Inventors:

- Omaha NE, US
Joseph R. GARLICH - Fort Collins CO, US
Donald L. DURDEN - Omaha NE, US

Assignee:

SignalRx Pharmaceuticals, Inc. - Omaha NE

International Classification:

C07D 495/04
C07D 493/04
C07D 519/00
A61P 35/04
A61P 27/00
A61P 37/00
A61P 29/00

Abstract:

The invention relates to methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral, bacterial or fungal infection, atherosclerosis, Type 1 or 2 diabetes, obesity, inflammatory disease, and/or SYK-associated disorder including by modulating biological processes through the inhibition of SYK alone, or in combination with inhibition of one or more of PI3 kinase including PI3K-gamma isoform, BET bromodomain proteins, CDK 4/6, and checkpoint proteins, comprising the administration of a compound(s) of Formula I-V (or pharmaceutically acceptable salts thereof) as defined herein.

US Patent:

20190367530, Dec 5, 2019

Filed:

Jan 26, 2018

Appl. No.:

16/481220

Inventors:

- Omaha NE, US
Joseph R. Garlich - Fort Collins CO, US
Donald L. Durden - Omaha NE, US

Assignee:

SignalRx Pharmaceuticals, Inc. - Omaha NE

International Classification:

C07D 495/04
A61P 35/00
A61K 45/06
A61K 31/5377
C07D 519/00
A61K 31/519
A61K 31/541
A61P 35/02

Abstract:

The invention relates to compounds and methods of treating diseases including but not limited to, cancer, non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis. Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of cell cycle checkpoint targets CDKs, and/or PI3 kinase, and/or bromodomain protein binding to substrates, comprising the administration of a compound(s) of Formula 1-VI (or pharmaceutically acceptable salts thereof) as defined herein.